Hormone Replacement Therapy Does Not Increase Severe Lupus Flares. Ann Intern Med. 2005;142:I-22. doi: 10.7326/0003-4819-142-12_Part_1-200506210-00001
Download citation file:
Published: Ann Intern Med. 2005;142(12_Part_1):I-22.
People with systemic lupus erythematosus (lupus) have antibodies that react against their tissues and organs. They may have a variety of findings and symptoms, including skin rashes that are worsened by sunlight, swollen and painful joints, ulcers in the nose or mouth, fatigue, fever, and inflammation of the lining around the lungs (pleuritis) or heart (pericarditis). Typically, symptoms flare up intermittently for a few weeks and then become less severe, sometimes for months or years.
We do not know what causes lupus, but it is much more common among women than men. It occurs most often after menarche and before menopause. Thus, some doctors think that estrogen hormones may play a role in activating the disease. Because of this belief, they may not recommend hormone replacement therapy (HRT) in menopausal women with lupus.
To see whether HRT increases disease activity and flares in menopausal women with lupus.
351 menopausal women with inactive or stable lupus (average age, 50 years). None had a history of blood clots in their legs or lungs.
Women were randomly assigned to HRT or a dummy pill (placebo). HRT consisted of conjugated estrogen (0.625 mg daily) and medroxyprogesterone (5 mg daily for days 1 through 12 of each month). Neither the women nor their doctors were told who received HRT or placebo. The researchers followed women monthly for 3 months and every 3 months thereafter for 1 year. At each visit, they asked women about symptoms and did tests to assess disease activity.
Severe flares of disease were infrequent in both groups, and were not increased in women taking HRT. Women taking HRT had mild to moderate flares of disease slightly more often than did women taking placebo. Four women taking HRT and 1 taking placebo developed some type of blood clot during the trial.
Women taking HRT for long periods have increased risk for adverse effects, such as blood clots, strokes, heart attacks, and breast cancer. This trial was too small to assess those risks, and it was stopped early by researchers when other studies showed those risks. In addition, women in this trial had inactive or stable lupus; those with very active lupus could not enter the trial until their disease was under better control.
HRT given for 1 year does not increase the risk for severe lupus flares but does slightly increase the risk for mild to moderate flares in menopausal women with lupus.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Rheumatology, Lupus Erythematosus.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only